The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

Swedish regulators cleared a clinical trial application, allowing Karolinska University Hospital investigators to begin studying 177Lu-AKIR001.

The companies will study genetic associations linked to autoimmune diseases to identify target genes as well as patients most likely to respond to therapy.

NEW YORK – Researchers have identified a gene signature that can predict whether early-stage breast cancer patients will ...

Avacta will tap into Tempus' real-world data and machine learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.

The recommendation was based on results from two Phase III trials showing that Tevimbra plus chemo improved overall survival over chemo alone.

The LRRK2 Investigative Therapeutics Exchange aims to advance basic sciences and support development of new drugs and LRRK2-specific biomarkers.

Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.

The firms aim to use Azure AI to process clinical notes, lab tests, genomic data, images, and other often inaccessible data to identify personalized treatments.

The test is designed to identify various obesity phenotypes that doctors can use to personalize treatment plans.

The company, which recently completed dosing TN-201 in an initial cohort of patients in the Phase Ib/II trial, will advance the study to the next dosing cohort.